Regen BioPharma (RGBP) Stock Price, News & Analysis

Company Overview

Regen BioPharma, Inc. is a development‐stage biotechnology company focused on advancing regenerative medicine and immunotherapy products through stem cell science. The company’s research efforts center on identifying and developing novel therapeutic candidates that harness the regenerative potential of adult and embryonic stem cells, with an emphasis on cancer, infectious and autoimmune diseases.

Its primary activities include the discovery and preclinical validation of stem cell‐derived receptors and peptides, the development of immuno‐oncology assets, and the filing of investigational new drug (IND) applications to support first‐in‐human studies. Regen BioPharma holds a portfolio of patents covering modified stem cell lines and proprietary methods for directing cell differentiation and modulating immune responses.

Founded in the mid‐1990s and headquartered in West Newton, Massachusetts, Regen BioPharma operates as a fully integrated research organization. The company collaborates with academic institutions, contract research organizations and industry partners across North America to advance its therapeutic programs. Regen BioPharma’s leadership team comprises seasoned executives and scientific advisors with backgrounds in biotechnology R&D, clinical development and patent strategy.

Key Stats

• Today's Range: $0.02 to $0.03
• 50-Day Range: $0.02 to $0.09
• 52-Week Range: $0.01 to $0.27
• Volume: 525,468 shs
• Average Volume: 78,972 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RGBP Stock Analysis - Frequently Asked Questions

How have RGBP shares performed this year?

Regen BioPharma's stock was trading at $0.0601 at the start of the year. Since then, RGBP shares have decreased by 72.0% and is now trading at $0.0168.

When did Regen BioPharma's stock split?

Regen BioPharma shares split before market open on Thursday, June 20th 2024.The 3-1 split was announced on Thursday, June 20th 2024. The newly created shares were issued to shareholders after the market closes on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

How do I buy shares of Regen BioPharma?

Shares of RGBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Regen BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Regen BioPharma investors own include Meta Platforms (META), Trans Global Group (TGGI), Exxe Group (AXXA), DraftKings (DKNG), Enzolytics (ENZC), Alcoa (AA) and Airborne Wireless Network (ABWN).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:RGBP
• CIK: 1589150
• Web: www.regenbiopharmainc.com
• Phone: (619) 722-5505
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A